• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·MDLN
Held by 3 Gurus
Share

Medline Inc. Stocks

$ 34.7Last Updated 30.09.2026

Issuer Rating

4/7
Performance

Average

Risk

Moderate

Recommendation

Hold

Market Cap

$ 29.58B

$ 34.7
Key Takeaways

Risk factor

Considerable default risk

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

In Guru Portfolios

Stephen Mandel

Portfolio Weight (%)

5.1%

Change

+0.71%

Fund

Lone Pine Capital

Bob Prince, Greg Jensen, Karen Karniol-Tambour

Portfolio Weight (%)

0.0%

Change

+0.00%

Fund

Bridgewater Associates

Kenneth Griffin

Portfolio Weight (%)

0.0%

Change

-0.02%

Fund

CITADEL ADVISORS LLC

Manager
Fund
Portfolio Weight (%)
Change
Stephen MandelLone Pine Capital5.1%+0.71%
Bob Prince, Greg Jensen, Karen Karniol-TambourBridgewater Associates0.0%+0.00%
Kenneth GriffinCITADEL ADVISORS LLC0.0%-0.02%

Latest news

09.09.2026 08:00

Tesla, IBM, McDonald’s: Evercore Names Stocks Threatened by AI Giants’ IPOs

21.12.2025 22:00

SpaceX in 'quiet period,' Medline had the listing of the year: what's important about the IPO by Dec. 21

18.12.2025 15:41

Medline shares soared 41% after this year's biggest IPO. Should you buy them?

17.12.2025 15:00

Biggest IPO of the year: shares of medical products giant Medline become available

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

No company description

Company Valuation

Fairly valued
4/7

From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. In particular, the stock is overpriced on P/E, of fair value on EV/

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of MDLN is 51.5 and suggests 47.2% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

01.10.2026 17:30

Shares of biotech company Capricor had their best day in a month. What inspired investors?

01.10.2026 16:53

From Coke to IMAX: 10 Companies Bloomberg Recommends Watching in the Fourth Quarter

01.10.2026 15:45

Morning in New York: Indices Seek Equilibrium

01.10.2026 15:13

Behind the scenes at the White House, IT company executives criticized Anthropic's CEO for AI alarmism

01.10.2026 14:44

An analyst named two companies that Novo should acquire to compete with Lilly

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026